Prolongation	prolongation	O	O
of	of	O	O
the	the	O	O
QT	qt	O	O
interval	interval	O	O
related	related	O	O
to	to	O	O
cisapride-diltiazem	cisapride-diltiazem	O	O
interaction	interaction	O	O
.	.	O	O

Cisapride	cisapride	O	O
,	,	O	O
a	a	O	O
cytochrome	cytochrome	B_chemicals	O
P450	p450	S_chemicals	O
3A4	3a4	I_chemicals	O
(	(	O	O
CYP3A4	cyp3a4	S_chemicals	O
)	)	O	O
substrate	substrate	S_chemicals	O
,	,	O	O
is	is	O	O
widely	widely	O	O
prescribed	prescribed	O	O
for	for	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
gastrointestinal	gastrointestinal	O	O
motility	motility	O	B_disease
disorders	disorders	O	I_disease
.	.	O	O

Prolongation	prolongation	O	O
of	of	O	O
QT	qt	O	O
interval	interval	O	O
,	,	O	O
torsades	torsades	O	B_disease
de	de	O	B_disease
pointes	pointes	O	I_disease
,	,	O	O
and	and	O	O
sudden	sudden	O	B_disease
cardiac	cardiac	O	B_disease
death	death	O	S_disease
have	have	O	O
been	been	O	O
reported	reported	O	O
after	after	O	O
concomitant	concomitant	O	O
administration	administration	O	O
with	with	O	O
erythromycin	erythromycin	S_chemicals	O
or	or	O	O
azole	azole	S_chemicals	O
antifungal	antifungal	B_chemicals	O
agents	agents	I_chemicals	O
,	,	O	O
but	but	O	O
not	not	O	O
with	with	O	O
other	other	O	O
CYP3A4	cyp3a4	B_chemicals	O
inhibitors	inhibitors	I_chemicals	O
.	.	O	O

A	a	O	O
possible	possible	O	O
drug	drug	S_chemicals	O
interaction	interaction	O	O
occurred	occurred	O	O
in	in	O	O
a	a	O	O
45-year-old	45-year-old	O	O
woman	woman	O	O
who	who	O	O
was	was	O	O
taking	taking	O	O
cisapride	cisapride	O	O
for	for	O	O
gastroesophageal	gastroesophageal	O	B_disease
reflux	reflux	O	I_disease
disorder	disorder	O	O
and	and	O	O
diltiazem	diltiazem	O	O
,	,	O	O
an	an	O	O
agent	agent	O	O
that	that	O	O
has	has	O	O
inhibitory	inhibitory	O	O
effect	effect	O	O
on	on	O	O
CYP3A4	cyp3a4	S_chemicals	O
,	,	O	O
for	for	O	O
hypertension	hypertension	O	S_disease
.	.	O	O

The	the	O	O
patient	patient	O	O
was	was	O	O
in	in	O	O
near	near	O	O
syncope	syncope	O	S_disease
and	and	O	O
had	had	O	O
QT-interval	qt-interval	O	O
prolongation	prolongation	O	O
.	.	O	O

After	after	O	O
discontinuing	discontinuing	O	O
cisapride	cisapride	O	O
,	,	O	O
the	the	O	O
QT	qt	O	O
interval	interval	O	O
returned	returned	O	O
to	to	O	O
normal	normal	O	O
and	and	O	O
symptoms	symptoms	O	O
did	did	O	O
not	not	O	O
recur	recur	O	O
.	.	O	O

We	we	O	O
suggest	suggest	O	O
that	that	O	O
caution	caution	O	O
be	be	O	O
taken	taken	O	O
when	when	O	O
cisapride	cisapride	O	O
is	is	O	O
prescribed	prescribed	O	O
with	with	O	O
any	any	O	O
potent	potent	O	O
inhibitor	inhibitor	O	O
of	of	O	O
CYP3A4	cyp3a4	S_chemicals	O
,	,	O	O
including	including	O	O
diltiazem	diltiazem	O	O
.	.	O	O

